| abstract |
The invention relates to new compounds for cancer therapy or diagnosis and more specifically to the use of a non-toxic B subunit of Shiga toxin mutant as a vector for diagnostic products or drugs in over-expressing Gb3 receptor cells, such compounds having the following formula: STxB-Z(n)-Cys-Y(m)- T wherein - STxB is the Shiga Toxin B subunit or a functional equivalent thereof, - Z(n) wehrein n is 0 or 1 and when n is 1, Z is an amino-acid residue devoidof sulfydryl group, or is a polypeptide, - Cys is the amino-acid residue for Cysteine, - T is a molecule linked by a covalent bound to the S part of Cys, selected in a group comprising: . agents for in vivo diagnosis, . cytotoxic agents, . prodrugs, or . enzymes for the conversion of a prodrug to a drug, - Y(m) wherein m is 0 or 1 and when m is 1, Y is a linker between T and Cys, said linker being either cleavable or not cleavable for the release of T after the internalization of the hybrid compound into said cells. |